These results are clinically appealing as combined treatment with an PD1/PD-L1 blocking agent and KIT or DNMT1 inhibitors, specifically in cisplatin refractory SCLC patients with evidence of deregulated DNMT1-KIT-PD-L1, may lead to a longer time to progression than is currently observed, and at the same time, increase the therapeutic index of these agents in SCLC management. The gene discussed is KIT; the disease is small cell lung carcinoma.